Literature DB >> 15792277

Ten lessons to be learned from the withdrawal of Vioxx (rofecoxib).

Xavier Carné1, Núria Cruz.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15792277     DOI: 10.1007/s10654-004-6856-1

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


× No keyword cloud information.
  23 in total

1.  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.

Authors:  Michael E Farkouh; Howard Kirshner; Robert A Harrington; Sean Ruland; Freek W A Verheugt; Thomas J Schnitzer; Gerd R Burmester; Eduardo Mysler; Marc C Hochberg; Michael Doherty; Elena Ehrsam; Xavier Gitton; Gerhard Krammer; Bernhard Mellein; Alberto Gimona; Patrice Matchaba; Christopher J Hawkey; James H Chesebro
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

2.  Coxibs and cardiovascular disease.

Authors:  Garret A Fitzgerald
Journal:  N Engl J Med       Date:  2004-10-06       Impact factor: 91.245

3.  Vioxx, the implosion of Merck, and aftershocks at the FDA.

Authors:  Richard Horton
Journal:  Lancet       Date:  2004 Dec 4-10       Impact factor: 79.321

4.  Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.

Authors:  M A Konstam; M R Weir; A Reicin; D Shapiro; R S Sperling; E Barr; B J Gertz
Journal:  Circulation       Date:  2001-11-06       Impact factor: 29.690

5.  [Drug related problems as a cause of hospital admission].

Authors:  María Teresa Martín; Carles Codina; Montserrat Tuset; Xavier Carné; Santiago Nogué; Josep Ribas
Journal:  Med Clin (Barc)       Date:  2002-02-23       Impact factor: 1.725

6.  Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.

Authors:  Peter Jüni; Linda Nartey; Stephan Reichenbach; Rebekka Sterchi; Paul A Dieppe; Matthias Egger
Journal:  Lancet       Date:  2004 Dec 4-10       Impact factor: 79.321

7.  Nonsteroidal anti-inflammatory drug use and acute myocardial infarction.

Authors:  Daniel H Solomon; Robert J Glynn; Raisa Levin; Jerry Avorn
Journal:  Arch Intern Med       Date:  2002-05-27

8.  Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac.

Authors:  William B White; Gerald Faich; Andrew Whelton; Clement Maurath; Nancy J Ridge; Kenneth M Verburg; G Steven Geis; James B Lefkowith
Journal:  Am J Cardiol       Date:  2002-02-15       Impact factor: 2.778

9.  Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.

Authors:  Daniel H Solomon; Sebastian Schneeweiss; Robert J Glynn; Yuka Kiyota; Raisa Levin; Helen Mogun; Jerry Avorn
Journal:  Circulation       Date:  2004-04-19       Impact factor: 29.690

10.  Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs.

Authors:  M J Langman; J Weil; P Wainwright; D H Lawson; M D Rawlins; R F Logan; M Murphy; M P Vessey; D G Colin-Jones
Journal:  Lancet       Date:  1994-04-30       Impact factor: 79.321

View more
  1 in total

1.  Gastrointestinal and Cardiovascular Risk of Nonsteroidal Anti-inflammatory Drugs.

Authors:  Abdulwahed Al-Saeed
Journal:  Oman Med J       Date:  2011-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.